Supporting Member Organizations

We are a global, science-led, patient-focused pharmaceutical company. We are dedicated to transforming the future of healthcare by unlocking the power of what science can do for people, society and the planet.

Children are the core of families. Child Core was created for caregivers to educate, empower, and encourage their children to experience medical settings with confidence, not anxiety. Our mission is to ensure children are supported and the family is strengthened during life?s changes.

At Chimerix, we are on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. With a focus in oncology, we are devoted to filling gaps in the treatment paradigm.

Dana-Farber Cancer Institute provides expert, compassionate, and equitable care to children, adults, and their families, while advancing the understanding, diagnosis, treatment, cure, and prevention of cancer and related diseases. We train new generations of clinicians and scientists, disseminate innovative patient therapies and scientific discoveries around the world, and reduce the impact of cancer, while at all times maintaining a focus on those communities who have been historically marginal

Day One Biopharmaceuticals is a clinical-stage biopharmaceutical company focused on accelerating new, promising targeted therapies for children and adults with cancer.

To transform the lives of patients by advancing innovative therapies that target MYC-driven diseases, starting with pediatric high-risk neural tumors. Through cutting-edge science and a commitment to addressing unmet medical needs, we aim to restore hope and deliver life-changing solutions globally.

The Focused Ultrasound Foundation was created to improve the lives of millions of people worldwide by accelerating the development of focused ultrasound, an early-stage noninvasive therapeutic technology with the potential to transform the treatment of many medical disorders. Since its establishment in 2006, it has become the largest non-governmental source of funding for focused ultrasound research.

THE LLS MISSION: Cure leukemia, lymphoma, Hodgkin’s disease and myeloma, and improve the quality of life of patients and their families.

Shaping the future for people with rare diseases and addressing global health challenges: We develop and support life science to remove the barriers that prevent promising discoveries from reaching people with rare diseases and in global health. Through our scientific capabilities, translational expertise and partnerships, we ensure great science achieves its potential and reaches patients faster.

We encourage, empower, and educate those living with Li-Fraumeni Syndrome by connecting them with care, resources, and others who are Living LFS.

Oncoheroes is groundbreaking biotech 100% focused on discovering, developing, and commercializing new therapies for children and adolescents with cancer. We intend to become the global leader in delivering new pediatric oncology drugs.

Relief From Cancer is a US-based nonprofit, assisting partner organizations in the USA and India to support cancer patients.

Servier is a privately held leader in oncology dedicated to bringing the promise of tomorrow to the patients we serve. Launched by Servier Group, a unique global organization operating in more than 150 countries and governed by a non-profit foundation, Servier in the U.S. is a privately held Oncology leader and has the resources and network of an established global pharmaceutical company, while operating with the nimble and entrepreneurial spirit of biotech.

At Syndax, we are advancing the next generation of targeted treatments to realize a future in which people with cancer live longer and better than ever before. We are a commercial stage oncology innovator seeking to develop first-in-class therapies in areas of significant unmet need such as acute leukemia and chronic graft-versus-host disease. Our team is committed to adhering to scientific excellence and dedicated to serving the patient community by delivering therapeutics that provide meaningful and differentiated clinical results and address urgent unmet need.

We enable students to thrive academically and personally because our empathetic understanding of learners? challenges, allows us to offer students holistic and innovative, solutions, that are personalized for students’ unique learning needs, developed to restore students’ confidence, and constructed to provide students with the tools they will need to overcome obstacles and achieve continued success.

Y-mAbs is a late-stage clinical biopharmaceutical company focused on the development and commercialization of novel, antibody-based therapeutic products for the treatment of cancer.nThe company has a broad and advanced product pipeline, including 2 pivotal-stage product candidates—naxitamab and omburtamab—which target tumors that express GD2 and B7-H3, respectively.